Targeting Antibiotic Tolerance, Pathogen by Pathogen

Antibiotic tolerance, the capacity of genetically susceptible bacteria to survive the lethal effects of antibiotic treatment, plays a critical and underappreciated role in the disease burden of bacterial infections. Here, we take a pathogen-by-pathogen approach to illustrate the clinical significanc...

Full description

Bibliographic Details
Main Authors: Meylan, Sylvain (Author), Andrews, Ian W. (Author), Collins, James J. (Author)
Other Authors: Massachusetts Institute of Technology. Institute for Medical Engineering & Science (Contributor), Massachusetts Institute of Technology. Synthetic Biology Center (Contributor)
Format: Article
Language:English
Published: Elsevier BV, 2020-07-01T22:27:58Z.
Subjects:
Online Access:Get fulltext
LEADER 01900 am a22002293u 4500
001 126048
042 |a dc 
100 1 0 |a Meylan, Sylvain  |e author 
100 1 0 |a Massachusetts Institute of Technology. Institute for Medical Engineering & Science  |e contributor 
100 1 0 |a Massachusetts Institute of Technology. Synthetic Biology Center  |e contributor 
700 1 0 |a Andrews, Ian W.  |e author 
700 1 0 |a Collins, James J.  |e author 
245 0 0 |a Targeting Antibiotic Tolerance, Pathogen by Pathogen 
260 |b Elsevier BV,   |c 2020-07-01T22:27:58Z. 
856 |z Get fulltext  |u https://hdl.handle.net/1721.1/126048 
520 |a Antibiotic tolerance, the capacity of genetically susceptible bacteria to survive the lethal effects of antibiotic treatment, plays a critical and underappreciated role in the disease burden of bacterial infections. Here, we take a pathogen-by-pathogen approach to illustrate the clinical significance of antibiotic tolerance and discuss how the physiology of specific pathogens in their infection environments impacts the mechanistic underpinnings of tolerance. We describe how these insights are leading to the development of species-specific therapeutic strategies for targeting antibiotic tolerance and highlight experimental platforms that are enabling us to better understand the complexities of drug-tolerant pathogens in in vivo settings. Lack of efficacy of antibiotic treatment presents a critical challenge to clinical management of bacterial infections. This review discusses the significance of antibiotic tolerance as the culprit of this challenge and its underlying mechanism as the target for future therapeutic development. 
520 |a National Science Foundation (Award 1122374) 
520 |a Defense Threat Reduction Agency (Award HDTRA1-15-1-0051) 
520 |a National Institutes of Health (Grant U19AI111276) 
546 |a en 
655 7 |a Article 
773 |t Cell